MOUNTAIN VIEW, Calif., June 18 /PRNewswire/ --
Microcide Pharmaceuticals, Inc. (Nasdaq: MCDE) will present an update of the
Company's progress at BIO 2001 International Investor and Partnering Forum in
San Diego.
This event will be web cast for investors at:
http://www.informedinvestors.com/iif_forums/event.cfm?forumID=194
After logging onto the website, look for Microcide Pharmaceuticals under
Informed Investors presenting companies.
WHO: James E. Rurka
President and Chief Executive Officer
Microcide Pharmaceuticals, Inc.
WHEN: June 26, 2001 at 9:45 a.m. (PDT)
WHERE: BIO 2001 International Convention & Exhibition
San Diego Convention Center
San Diego, CA
CONTACT: Donald D. Huffman, VP of Finance and Corporate
Development & CFO,
650-428-3557 http://www.microcide.com
Microcide is a biopharmaceutical company committed to the discovery,
development and commercialization of novel antimicrobials for the improved
treatment of serious bacterial, fungal and viral infections. The Company's
three discovery research platforms address the growing problems of antibiotic
resistance and the need for improved antifungal and antiviral therapeutics.
The Company's Cephalosporin Antibiotics and Efflux Pump Inhibition platforms
focus on developing novel antibiotics and antibiotic potentiators (efflux
inhibitors) to directly address existing bacterial and fungal resistance
problems. Microcide's Microbial Genomics platform (VALID System) utilizes
proprietary bacterial, fungal and viral genetics and genomics tools to
discover entirely new classes of antimicrobial agents.
The statements contained in this press release which are not historical
facts may be deemed to contain forward-looking statements. Actual results may
differ materially from those expressed or implied in any forward-looking
statement as a result of certain risks and uncertainties. For a discussion of
risks and uncertainties affecting Microcide's business, see its annual report
on Form 10-K/A for the year ended December 31, 2000 and its quarterly report
on Form 10-Q for the quarter ended March 31, 2001. Actual results and timing
of certain events could differ materially from those indicated in the
forward-looking statements as a result of these or other factors.
SOURCE Microcide Pharmaceuticals, Inc.
 back to top
Related links:
http://www.microcide.com
Company News On-Call:
http://www.prnewswire.com/comp/113880.html or fax,
800-758-5804, ext. 113880
CONTACT:
Donald D. Huffman, VP of Finance and
Corporate Development & CFO of Microcide Pharmaceuticals, Inc.,
650-428-3557
|
